These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 897965)

  • 21. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue.
    Pitman SW; Miller D; Weichselbaum R
    Laryngoscope; 1978 Apr; 88(4):632-8. PubMed ID: 306011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.
    Colella E; Merlano M; Blengio F; Angelini F; Ausili Cefaro GP; Scasso F; Lo Russo V; Cirulli S; Giannarelli D; Cognetti F
    Eur J Cancer; 1994; 30A(7):928-30. PubMed ID: 7946585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current concepts of chemotherapy combined with other modalities for head and neck cancer.
    DeWys WD
    Can J Otolaryngol; 1975; 4(2):195-204. PubMed ID: 49217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant chemoimmunotherapy of head and neck cancer.
    Taylor SG; Sisson GA; Bytell DE
    Recent Results Cancer Res; 1978; 68():297-308. PubMed ID: 313586
    [No Abstract]   [Full Text] [Related]  

  • 26. Methotrexate treatment of advanced head and neck cancers: a dose response evaluation.
    Woods RL; Fox RM; Tattersall MH
    Cancer Treat Rep; 1981; 65 Suppl 1():155-9. PubMed ID: 7034929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer.
    Vogl SE; Schoenfeld DA; Kaplan BH; Lerner HJ; Engstrom PF; Horton J
    Cancer; 1985 Aug; 56(3):432-42. PubMed ID: 2408735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose methotrexate and cis-platinum in the treatment of recurrent head and neck cancer.
    Jacobs C
    Recent Results Cancer Res; 1981; 76():290-5. PubMed ID: 7015433
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas--a prospective, randomized study.
    Rentschler RE; Wilbur DW; Petti GH; Chonkich GD; Hilliard DA; Camacho ES; Thorpe RB
    J Clin Oncol; 1987 Feb; 5(2):278-85. PubMed ID: 3806169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Indications for cytostatic therapy of recurrent cancer].
    Schröder M; Stennert E; von Heyden HW; Scherpe A
    HNO; 1984 Jun; 32(6):245-8. PubMed ID: 6206035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
    Schornagel JH; Verweij J; de Mulder PH; Cognetti F; Vermorken JB; Cappelaere P; Armand JP; Wildiers J; de Graeff A; Clavel M
    J Clin Oncol; 1995 Jul; 13(7):1649-55. PubMed ID: 7602354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of chemotherapy in untreated squamous-cell carcinoma of the head and neck.
    Bahadur S; Tandon DA; Kacker SK
    J Laryngol Otol; 1984 Nov; 98(11):1115-9. PubMed ID: 6491501
    [No Abstract]   [Full Text] [Related]  

  • 33. Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck.
    Lundy J; Wanebo H; Pinsky C; Strong E; Oettgen H
    Am J Surg; 1974 Oct; 128(4):530-3. PubMed ID: 4429642
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of methotrexate and 5-FU for recurrent head and neck cancer.
    Jacobs C
    Cancer Treat Rep; 1982 Nov; 66(11):1925-8. PubMed ID: 6754074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell carcinoma of the head and neck.
    Drelichman A; Cummings G; Al-Sarraf M
    Cancer; 1983 Aug; 52(3):399-403. PubMed ID: 6190548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy in recurrent heat and neck cancer.
    Simmonds WP
    Otolaryngol Clin North Am; 1974 Feb; 7(1):205-15. PubMed ID: 4130287
    [No Abstract]   [Full Text] [Related]  

  • 37. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
    Patil V; Noronha V; Krishna V; Joshi A; Prabhash K
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):388. PubMed ID: 23434353
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
    Winquist E; Al-Rasheedy I; Nichols AC; Palma DA; Stitt L
    Cancer Treat Rev; 2014 Oct; 40(9):1073-9. PubMed ID: 25200522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
    Sakoda T; Morizane R; Nakahara K; Enomoto Y; Nosaka A; Enomoto T; Kitano H
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1451-5. PubMed ID: 19755812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.